$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

$ekso Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000114420416100556 Filed on May 10, 2016

Income Statement

Concept	2016 Q2	2016 Q1	2015 Q1
Revenue	$1.552M	$8.486M	$1.689M
YoY Change	-26.58%	402.43%	59.04%
Cost Of Revenue	$1.349M	$319.0K	$1.286M
YoY Change	-16.32%	-75.19%	120.96%
Gross Profit	$203.0K	$1.498M	$403.0K
YoY Change	-59.56%	271.71%	-16.04%
Gross Profit Margin	13.08%	17.65%	23.86%
Selling, General & Admin	$5.378M	$5.990M	$3.510M
YoY Change	22.37%	70.66%	-2.56%
% of Gross Profit	2649.26%	399.87%	870.97%
Research & Development	$2.221M	$2.149M	$983.0K
YoY Change	27.5%	118.62%	27.9%
% of Gross Profit	1094.09%	143.46%	243.92%
Depreciation & Amortization	$470.0K	$440.0K	$200.0K
YoY Change	113.64%	120.0%	27.39%
% of Gross Profit	231.53%	29.37%	49.63%
Operating Expenses	$7.599M	$8.140M	$4.496M
YoY Change	23.82%	81.05%	2.86%
Operating Profit	-$7.396M	-$6.642M	-$4.093M
YoY Change	31.25%	62.28%	5.19%
Interest Expense	-$34.00K	$6.000K	-$22.00K
YoY Change	-1233.33%	-127.27%	-105.15%
% of Operating Profit
Other Income/Expense, Net	$1.631M	$2.991M	-$23.00K
YoY Change	-16410.0%	-13104.35%	91.67%
Pretax Income	-$5.770M	-$3.650M	-$4.120M
YoY Change	2.12%	-11.41%	-94.96%
Income Tax
% Of Pretax Income
Net Earnings	-$5.765M	-$3.651M	-$4.115M
YoY Change	2.13%	-11.28%	-94.97%
Net Earnings / Revenue	-371.46%	-43.02%	-243.64%
Basic Earnings Per Share	-$0.61	-$0.44
Diluted Earnings Per Share	-$0.61	-$0.44	-$4.247M
COMMON SHARES
Basic Shares Outstanding	16.18M shares	15.39M shares	101.8M shares
Diluted Shares Outstanding		15.39M shares

Balance Sheet

Concept	2016 Q2	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.660M	$12.31M	$21.13M
YoY Change	-71.32%	-41.74%	44.92%
Cash & Equivalents	$4.661M	$12.31M	$21.13M
Short-Term Investments
Other Short-Term Assets	$690.0K	$1.000M	$2.130M
YoY Change	-70.64%	-53.05%	54.35%
Inventory	$2.410M	$2.531M	$840.0K
Prepaid Expenses
Receivables	$1.570M	$2.383M	$1.460M
Other Receivables	$40.00K	$0.00	$0.00
Total Short-Term Assets	$9.370M	$18.22M	$25.55M
YoY Change	-57.76%	-28.68%	35.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.580M	$2.617M	$2.183M
YoY Change	19.78%	19.88%	23.78%
Goodwill		$189.0K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$90.00K	$93.00K	$55.00K
YoY Change	63.64%	69.09%	1.12%
Total Long-Term Assets	$4.210M	$4.330M	$4.483M
YoY Change	-10.88%	-3.41%	52.21%
TOTAL ASSETS
Total Short-Term Assets	$9.370M	$18.22M	$25.55M
Total Long-Term Assets	$4.210M	$4.330M	$4.483M
Total Assets	$13.58M	$22.55M	$30.03M
YoY Change	-49.53%	-24.91%	37.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.070M	$3.618M	$1.464M
YoY Change	-10.23%	147.13%	40.19%
Accrued Expenses	$2.130M	$2.928M	$1.657M
YoY Change	7.79%	76.7%	5.82%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$80.00K	$80.00K	$40.00K
YoY Change	100.0%	100.0%	0.0%
Total Short-Term Liabilities	$5.790M	$7.849M	$6.708M
YoY Change	-30.72%	17.01%	19.5%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$70.00K
YoY Change	-100.0%	-100.0%	-36.36%
Other Long-Term Liabilities	$6.220M	$205.0K	$4.160M
YoY Change	36.4%	-95.07%	-95.41%
Total Long-Term Liabilities	$6.220M	$205.0K	$4.230M
YoY Change	34.92%	-95.15%	-95.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.790M	$7.849M	$6.708M
Total Long-Term Liabilities	$6.220M	$205.0K	$4.230M
Total Liabilities	$12.01M	$15.80M	$10.94M
YoY Change	-7.41%	44.46%	-88.65%
SHAREHOLDERS EQUITY
Retained Earnings		-$95.04M	-$75.92M
YoY Change		25.19%	-36.63%
Common Stock	$16.00K	$109.0K	$102.0K
YoY Change	-84.31%	6.86%	29.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.560M	$6.753M	$19.10M
YoY Change
Total Liabilities & Shareholders Equity	$13.58M	$22.55M	$30.03M
YoY Change	-49.53%	-24.91%	37.76%

Cashflow Statement

Concept	2016 Q2	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	-$5.765M	-$3.651M	-$4.115M
YoY Change	2.13%	-11.28%	-94.97%
Depreciation, Depletion And Amortization	$470.0K	$440.0K	$200.0K
YoY Change	113.64%	120.0%	27.39%
Cash From Operating Activities	-$7.330M	-$6.790M	-$3.830M
YoY Change	58.32%	77.28%	-31.12%
INVESTING ACTIVITIES
Capital Expenditures	-$310.0K	$285.0K	$281.0K
YoY Change	10.71%	1.42%	13.31%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$310.0K	-$290.0K	-$280.0K
YoY Change	10.71%	3.57%	100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-10.00K	-160.0K	50.00K
YoY Change	-133.33%	-420.0%	-99.74%
NET CHANGE
Cash From Operating Activities	-7.330M	-6.790M	-3.830M
Cash From Investing Activities	-310.0K	-290.0K	-280.0K
Cash From Financing Activities	-10.00K	-160.0K	50.00K
Net Change In Cash	-7.650M	-7.240M	-4.060M
YoY Change	56.76%	78.33%	-129.46%
FREE CASH FLOW
Cash From Operating Activities	-$7.330M	-$6.790M	-$3.830M
Capital Expenditures	-$310.0K	$285.0K	$281.0K
Free Cash Flow	-$7.020M	-$7.075M	-$4.111M
YoY Change	61.38%	72.1%	-29.22%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2694000	USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	8057000	USD
CY2016Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	429000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	8486000	USD
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	1689000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6669000	USD
CY2016Q1	us-gaap	Cost Of Services CostOfServices	319000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2149000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	8140000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6642000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2991000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-3651000	USD
CY2016Q1	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	-3124000	USD
CY2015Q1	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	0	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6775000	USD
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	EKSO BIONICS HOLDINGS, INC.
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Trading Symbol TradingSymbol	PNMD
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001549084
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16182889	shares
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4093000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-22000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12314000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19552000	USD
CY2016Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2383000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2069000	USD
CY2016Q1	us-gaap	Inventory Net InventoryNet	2531000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	1056000	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	738000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	436000	USD
CY2016Q1	us-gaap	Deferred Costs Current DeferredCostsCurrent	255000	USD
CY2015Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	2088000	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	18221000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	25201000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2617000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2625000	USD
CY2016Q1	us-gaap	Deferred Costs DeferredCosts	0	USD
CY2015Q4	us-gaap	Deferred Costs DeferredCosts	2502000	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	93000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	97000	USD
CY2016Q1	us-gaap	Assets Assets	22551000	USD
CY2015Q4	us-gaap	Assets Assets	32198000	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3618000	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2928000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1885000	USD
CY2016Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1222000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3960000	USD
CY2016Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	81000	USD
CY2015Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	80000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7849000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8619000	USD
CY2016Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	766000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4613000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-4115000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	4496000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1662000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	985000	USD
CY2015Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	704000	USD
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	798000	USD
CY2015Q1	us-gaap	Cost Of Services CostOfServices	488000	USD
CY2015Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1286000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3488000	USD
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15604000	shares
CY2016Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	205000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	195000	USD
CY2016Q1	us-gaap	Liabilities Liabilities	15798000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	23390000	USD
CY2016Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	101686000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	100094000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-95042000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-91391000	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	6753000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	8808000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22551000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32198000	USD
CY2016Q1	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1431000	USD
CY2015Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1584000	USD
CY2016Q1	us-gaap	Goodwill Goodwill	189000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	189000	USD
CY2016Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	6210000	USD
CY2015Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	9195000	USD
CY2016Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	768000	USD
CY2015Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	768000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4115000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25190000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	28000	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	31000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7238000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4057000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21133000	USD
CY2016Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	19000	USD
CY2015Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	11000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-164000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	52000	USD
CY2016Q1	pnmd	Average Monthly Cash Burn AverageMonthlyCashBurn	1800000	USD
CY2016Q1	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	255000	USD
CY2016Q1	pnmd	Gain Loss On Warrant Liability GainLossOnWarrantLiability	2985000	USD
CY2015Q1	pnmd	Gain Loss On Warrant Liability GainLossOnWarrantLiability	0	USD
CY2016Q1	us-gaap	Depreciation Depreciation	440000	USD
CY2016Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2015Q1	us-gaap	Inventory Write Down InventoryWriteDown	45000	USD
CY2016Q1	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	-9000	USD
CY2015Q1	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	-10000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	349000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-94000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	261000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	59000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	354000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	681000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-721000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	323000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6789000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3828000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	285000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	281000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-285000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-281000	USD
CY2015Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	4590000	USD
CY2016Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1563000	USD
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1464000	USD
CY2016Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	158000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	257000	USD
CY2016Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	216000	USD
CY2015Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	0	USD
CY2016Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	80000	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	164000	USD
CY2016Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	96000	USD
CY2015Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	86000	USD
CY2016Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	224000	USD
CY2016Q1	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	18000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15388000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14542000	shares
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2016Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	173000	USD
CY2016Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2015Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	32000	USD
CY2016Q1	us-gaap	Capital Lease Obligations CapitalLeaseObligations	206000	USD
CY2016Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	125000	USD
CY2016Q1	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	50000	USD
CY2016Q1	pnmd	Supply Agreement Minimum Annual Price SupplyAgreementMinimumAnnualPrice	157000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7373000	shares
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3462000	shares
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	9000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	13000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	9000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	13000	shares
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	71429000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	71429000	shares
CY2016Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	6000	USD
CY2015Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-22000	USD
CY2016Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of the associated costs, future warranty costs, maintenance and planned improvement costs associated with medical device units sold prior to 2016, useful lives assigned to long-lived assets, realizability of deferred tax assets, the valuation of options and warrants, and contingencies. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Concentration of Credit Risk and Other Risks and Uncertainties</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. We maintain our cash accounts in excess of federally insured limits. However, we believe we are not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held.  We extend credit to customers in the normal course of business and perform ongoing credit evaluations of our customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. We do not require collateral from our customers to secure accounts receivable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Accounts receivable are derived from the sale of products shipped and services performed for customers located in the U.S. and throughout the world. Invoices are aged based on contractual terms with the customer. We review accounts receivable for collectability and provide an allowance for credit losses, as needed. We have not experienced any material losses related to accounts receivable as of March 31, 2016 and December 31, 2015. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We do not enter into any foreign currency hedging agreements and are susceptible to gains and losses from foreign currency fluctuations. To date, we have not experienced significant gains or losses upon settling foreign currency denominated accounts receivable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of March 31, 2016, we had one customer with accounts receivable balances totaling <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% or more of our total accounts receivable (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">16</font>%), compared with one customer as of December 31, 2015 (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font>%).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In the three months ended March 31, 2016, we had four customers with billed revenue of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% or more of total billed revenue (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">27</font>%, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20</font>%, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>%), compared with two customers in the three months ended March 31, 2015 (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">17</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 16</font>%).</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	64000	USD
CY2015Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	71000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1610000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	179000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1431000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	404000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	537000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	490000	USD
CY2015Q4	pnmd	Accrued Maintenance Current AccruedMaintenanceCurrent	0	USD
CY2016Q1	pnmd	Accrued Maintenance Current AccruedMaintenanceCurrent	911000	USD
CY2016Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	68000	USD
CY2016Q1	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Two LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo	60000	USD
CY2016Q1	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Three LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree	37000	USD
CY2016Q1	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Four LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour	37000	USD
CY2016Q1	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Five LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive	22000	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0141	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0178	pure
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0192	pure
CY2016Q1	pnmd	Reduction In Net Loss Attributable To Common Stock Holders ReductionInNetLossAttributableToCommonStockHolders	2358000	USD
CY2016Q1	pnmd	Reduction In Net Loss Per Share Attributable To Common Stock Holders ReductionInNetLossPerShareAttributableToCommonStockHolders	0.15
CY2015Q4	pnmd	Product Maintenance Warranty Liabilities Current Noncurrent ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent	0	USD
CY2016Q1	pnmd	Product Maintenance Warranty Addition ProductMaintenanceWarrantyAddition	1166000	USD
CY2016Q1	pnmd	Product Maintenance Warranty Expense ProductMaintenanceWarrantyExpense	0	USD
CY2016Q1	pnmd	Product Maintenance Warranty Payments ProductMaintenanceWarrantyPayments	0	USD
CY2016Q1	pnmd	Product Maintenance Warranty Liabilities Current ProductMaintenanceWarrantyLiabilitiesCurrent	1127000	USD
CY2016Q1	pnmd	Product Maintenance Warranty Liabilities Noncurrent ProductMaintenanceWarrantyLiabilitiesNoncurrent	39000	USD
CY2016Q1	pnmd	Product Maintenance Warranty Liabilities Current Noncurrent ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent	1166000	USD
CY2014Q4	pnmd	Product Maintenance Warranty Liabilities Current Noncurrent ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent	126000	USD
CY2015Q1	pnmd	Product Maintenance Warranty Addition ProductMaintenanceWarrantyAddition	0	USD
CY2015Q1	pnmd	Product Maintenance Warranty Expense ProductMaintenanceWarrantyExpense	-17000	USD
CY2015Q1	pnmd	Product Maintenance Warranty Payments ProductMaintenanceWarrantyPayments	0	USD
CY2015Q1	pnmd	Product Maintenance Warranty Liabilities Current Noncurrent ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent	109000	USD
CY2015Q1	pnmd	Product Maintenance Warranty Liabilities Current ProductMaintenanceWarrantyLiabilitiesCurrent	109000	USD
CY2015Q1	pnmd	Product Maintenance Warranty Liabilities Noncurrent ProductMaintenanceWarrantyLiabilitiesNoncurrent	0	USD
CY2016Q1	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	911000	USD
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4085000	shares
CY2016Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4085000	shares
CY2016Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	4000	shares
CY2016Q1	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	566000	shares
CY2016Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3124000	USD
CY2016Q1	pnmd	Unamortized Warrant Discount UnamortizedWarrantDiscount	7221000	USD
CY2015Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	9195000	USD
CY2016Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2985000	USD
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15604000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0124	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.77	pure
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.73	pure
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	349000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1574000	USD
CY2016Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2017-05-31
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15027000	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15027000	shares
CY2016Q1	us-gaap	Deferred Revenue DeferredRevenue	1988000	USD
CY2015Q4	us-gaap	Deferred Revenue DeferredRevenue	8573000	USD
CY2016Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	109000	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	105000	USD

Files In Submission

Name	View Source	Status
0001144204-16-100556-index-headers.html	Edgar Link	pending
0001144204-16-100556-index.html	Edgar Link	pending
0001144204-16-100556.txt	Edgar Link	pending
0001144204-16-100556-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pnmd-20160331.xml	Edgar Link	completed
pnmd-20160331.xsd	Edgar Link	pending
pnmd-20160331_cal.xml	Edgar Link	unprocessable
pnmd-20160331_def.xml	Edgar Link	unprocessable
pnmd-20160331_lab.xml	Edgar Link	unprocessable
pnmd-20160331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v438707_10q.htm	Edgar Link	pending
v438707_ex31-1.htm	Edgar Link	pending
v438707_ex31-2.htm	Edgar Link	pending
v438707_ex32-1.htm	Edgar Link	pending
v438707_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

2016 Q2 Form 10-Q Financial Statement

#000114420416100556 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO EKSO BIONICS HOLDINGS, INC. Stock $ekso

2016 Q2 Form 10-Q Financial Statement

#000114420416100556 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso